Avanir Pharmaceuticals (AVNR) jumps 14% premarket after the Committee for Medicinal Products for...


Avanir Pharmaceuticals (AVNR) jumps 14% premarket after the Committee for Medicinal Products for Human Use recommends approval of NUEDEXTA for the treatment of pseudobulbar affect. The company says the positive opinion is an important milestone on the road to getting "the only evidence-based treatment for PBA approved in the European Union."

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs